Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial

Main Article Content

Mark Lebwohl
Linda Stein Gold
Melinda J. Gooderham
Kim A. Papp
Laura K. Ferris
David N. Adam
H. Chih-ho Hong
Leon H. Kircik
Matthew Zirwas
Patrick Burnett
Robert Higham


Plaque Psoriasis, roflumilast, phosphodiesterase 4 inhibitor


1. Dong C, et al. J Pharmacol Exp Ther2016;358:413–422.

2. Lebwohl MG, et al. N Engl J Med 2020;383:229–239.

3. Stein Gold LS, et al. Poster presented at: Innovations in Dermatology; March 16-20, 2021; Virtual.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>